Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIR-NP is an experimental optical imaging agent composed of the deep infrared (DIR) fluorescent dye encapsulated within non-targeted poly(lactic-co-glycolic acid) (PLGA) nanoparticles. Developed at the Yale University School of Medicine, it is utilized as a control or passive targeting agent in studies aimed at improving the intraoperative detection of epithelial ovarian cancer micrometastases. The nanoparticle platform is designed to accumulate in the tumor microenvironment, allowing for the visualization of microscopic residual disease that is otherwise difficult to distinguish during surgery. In preclinical models, DIR-NP has demonstrated the ability to delineate small tumor foci, although with lower efficiency compared to RGD-peptide-targeted versions (DIR-RGD-NP).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DIR-NP.